Description

Iguratimod (T-614) is a novel small-molecule disease-modifying anti-rheumatic drug (DMARD) with potent anti-inflammatory and immunomodulatory effects. It acts by inhibiting NF-?B activation and selectively suppresses COX?2 and multiple pro-inflammatory cytokines (e.g., TNF-?, IL?6, IL?1?, IL?8). It also inhibits macrophage migration inhibitory factor (MIF), providing both anti-inflammatory and cartilage-protective properties.

The Aidingxin formulation delivers a precise 25?mg dose per tablet, suitable for preclinical and pharmacological research in arthritis, autoimmune models, and cytokine signaling studies. Manufactured by Hainan Simcere Pharmaceutical Co., Ltd., with approval under China NMPA registration number H20110084, product code 86905849000689, and barcode 6920209687007.

?? For laboratory research use only. Not for clinical, therapeutic, or veterinary applications.

Iguratimod Tablets Product Specifications

Iguratimod Tablets Mechanism & Research Applications

• Mechanism: Inhibits NF??B activation, suppresses COX?2 and pro-inflammatory cytokines, and inhibits MIF with an IC?? ~6.8??M.

• Research Applications:

  • Rheumatoid arthritis and arthritis models

  • Cytokine signaling and inflammatory pathway assays

  • Cartilage/bone protection studies

  • Combination therapy with MTX or biologic agents

  • Immune cell modulation and macrophage function assays

Iguratimod Tablets Side Effects (Observed in Research Models)

Preclinical and clinical data report the following potential side effects:

• Elevated liver enzymes (transaminases)

• Gastrointestinal discomfort (nausea, abdominal pain)

• Skin rash or pruritus

• Mild hematological changes (e.g., thrombocytopenia)
  Monitor liver function and hematologic parameters in in vivo studies.

Safety & Handling

• Usage: Laboratory research only; not approved for therapeutic, clinical, or veterinary use

• PPE: Use gloves, lab coat, and eye protection

• Storage: Keep sealed below 25?°C, avoid light and moisture

• Disposal: Dispose unused tablets as per institutional chemical safety protocols

Core Keywords

Iguratimod tablets, Aidingxin Iguratimod, 25?mg T?614 tablet, lab-grade DMARD, rheumatoid research compound, immune modulation reagent, NMPA H20110084 Iguratimod, Simcere Iguratimod, wholesale Iguratimod tablets

Research Use Disclaimer

This product is exclusively intended for laboratory research and is not approved for clinical, diagnostic, therapeutic, or veterinary use. Misuse may pose safety or regulatory risks. Always comply with institutional biosafety and handling guidelines.